Skip to content
Open access

Incorporation of a pH-Sensitive Linker into Lipid–ASO Conjugates Drives Increased Endosomal Membrane Remodeling Events

Sep 2026 · Nucleic Acid Therapeutics · Vol 36, pp. 287 - 299 · 0 citations · 46 references
Medicine

TL;DR

It is shown that introducing a pH-sensitive linker in C16 lipid- and C22 lipid-conjugated ASOs increases endosomal remodeling events detected via a Galectin 9 reporter imaging assay, despite similar levels of ASO cellular uptake, and incorporation of a pH-sensitive linker can lead to improved gene silencing in vitro.

Abstract

Oligonucleotide therapeutics have great potential for the treatment of previously “undruggable” human diseases; however, their broad utility is limited by challenges in delivery and achieving sufficient endosomal escape. Systemic delivery of antisense oligonucleotides (ASOs) results in their primary accumulation in the liver and kidneys, limiting their effectiveness in targeting RNAs in other tissues. Conjugation to specific lipids has been employed to boost productive delivery of oligonucleotides to nonhepatic tissues such as heart and skeletal muscle. Once oligonucleotides have entered the right cell type, they then need to escape the endosomal lipid bilayer to reach their RNA targets in the nucleus and cytoplasm. In this article, we show that introducing a pH-sensitive linker in C16 lipid- and C22 lipid-conjugated ASOs increases endosomal remodeling events detected via a Galectin 9 reporter imaging assay, despite similar levels of ASO cellular uptake. Furthermore, incorporation of a pH-sensitive linker can lead to improved gene silencing in vitro. These data suggest that decoupling the lipid from the ASO is a promising approach to improve ASO endosomal escape and activity. Therefore, pH-sensitive linkers offer a novel strategy to expand the potential use of oligonucleotide therapeutics.

Read PDF

Similar papers

Open access Sep 2026

Precise pH-triggered cleavage of PEG-lipid conjugates drives endosomal escape of siRNA from fusogenic lipid-based nanoparticles.

Novel pH-triggered RNA-LNPs (ZK2 LNPs) that comprise PEG-lipid oxime conjugates (5 mol%), prepared in situ using pH-reversible aminoxy-aldehyde click chemistry represent a powerful next generation LNP technology and demonstrate excellent LNP tolerability in vivo.

Zdeněk Kratochvíl, Dattary Shivajirao Bhosale, Melanie Schürz et al. · 0 citations
Open access Aug 2026

Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems

The importance of formulation optimization in improving nucleic acid delivery is highlighted and practical insights for enhancing peptide- and lipid-based therapeutic platforms are provided.

D. Daniele, Z. Hein, O. Saher et al. · 0 citations
Sep 2026

Cysteine/GSH-Responsive Lipid Switch Development for Liposome Triggered Cargo Release

It is demonstrated that SLPC can act as a potent liposomal platform to achieve cysteine/GSH-triggered controlled content release toward the goal of targeted drug delivery to diseased cells.

Mahbub Ullah, Kazi R. Shahriar, Mayesha B. Mustafa et al. · 0 citations
#gene editing Open access Oct 2026

Delivering the Undeliverable: Rational Engineering of Membrane-Based and Synthetic Nanoparticle Platforms

Delivering therapeutic macromolecules to defined cell populations in vivo remains a central unsolved problem in biomedicine. Proteins, nucleic acids and viral vectors are cleared by phagocytes, degraded by enzymes, blocked by endothelial and interstitial barriers, and trapped in acidifying endolysosomes. Pre-existing i...

Qiang-Bing Yang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.